现代免疫学在感染性疾病、过敏性疾病、肿瘤和神经系统疾病中的研究进展

doi:10.3969/j.issn.1006-7795.2023.02.001

摘要/Abstract

摘要：

免疫学(immunology)作为一门交叉学科，其研究内容涉及多种学科和不同疾病的诸多方面。近年来，免疫学在基础和临床研究方面取得诸多突破性进展，并深化了对众多常见疾病中的免疫应答及调控机制的认识,为揭示免疫相关疾病的发病机制提供了新的科学依据和临床防治手段。本文对研究较为深入的免疫学中关键的细胞和重要信号通路以及细胞因子等在感染性疾病、过敏性疾病、肿瘤和神经系统疾病这四个方面的进展概况加以概述。

关键词: 感染性疾病, 过敏性疾病, 肿瘤, 神经系统疾病, 免疫

Abstract:

Immunology, as an interdisciplinary subject, involves a variety of subjects and many aspects of different diseases. For the past few years, many breakthroughs have been made in basic and clinical research of immunology, which has deepened the understanding of immunological response and its regulatory mechanism in many common diseases. These findings provide a new scientific basis and clinical means of prevention and treatment for the pathogenesis of immune-related diseases. In this review, we focus on the key cells and important signaling pathways in immunology, and the role of cytokines in infectious diseases, allergic diseases, tumors and neurological disorders.

Key words: infectious diseases, allergic diseases, tumor, neurological diseases, immunity

中图分类号:

R392

陈彦, 张须龙, 许江南, 贾玉峰, 孙英. 现代免疫学在感染性疾病、过敏性疾病、肿瘤和神经系统疾病中的研究进展[J]. 首都医科大学学报, 2023, 44(2): 179-185.

Chen Yan, Zhang Xulong, Xu Jiangnan, Jia Yufeng, Sun Ying. Advances in modern immunology in infectious diseases, allergic diseases, tumors, and neurological disorders[J]. Journal of Capital Medical University, 2023, 44(2): 179-185.

参考文献

［1］Wu X, Yao D D, Bao L L, et al. Ficolin A derived from local macrophages and neutrophils protects against lipopolysaccharide-induced acute lung injury by activating complement［J］. Immunol Cell Biol, 2020, 98(7):595－606.
［2］Wu X, Bao L L, Hu Z Q, et al. Ficolin A exacerbates severe H1N1 influenza virus infection-induced acute lung immunopathological injury via excessive complement activation［J］. Cell Mol Immunol, 2021, 18(9):2278－2280.
［3］Ren X W, Wen W, Fan X Y, et al. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas［J］. Cell, 2021, 184(7):1895－1913.e19.
［4］Liao M F, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19［J］. Nat Med, 2020, 26(6):842－844.
［5］Melms J C, Biermann J, Huang H C, et al. A molecular single-cell lung atlas of lethal COVID-19［J］. Nature, 2021, 595(7865):114－119.
［6］Wang L, Wen M Y, Cao X T. Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to DNA viruses［J］. Science, 2019, 365(6454):eaav0758.
［7］Solis A G, Bielecki P, Steach H R, et al. Mechanosensation of cyclical force by PIEZO1 is essential for innate immunity ［J］. Nature, 2019, 573(7772):69－74.
［8］Xu X L, Han M F, Li T T, et al. Effective treatment of severe COVID-19 patients with tocilizumab［J］. Proc Natl Acad Sci U S A, 2020, 117(20):10970－10975.
［9］Liu B, Bao L L, Wang L, et al. Anti-IFN-γ therapy alleviates acute lung injury induced by severe influenza A (H1N1) pdm09 infection in mice［J］. J Microbiol Immunol Infect, 2021, 54(3):396－403.
［10］Liu S, Li H, Wang Y M, et al. High expression of IL-36γ in influenza patients regulates interferon signaling pathway and causes programmed cell death during influenza virus infection［J］. Front Immunol, 2020, 11:552606.
［11］Xue C X, Wen M J, Bao L L, et al. Vγ4+γδT cells aggravate severe H1N1 influenza virus infection-induced acute pulmonary immunopathological injury via secreting interleukin-17A［J］. Front Immunol, 2017, 8:1054.
［12］Zhou Z W, He H B, Wang K, et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells［J］. Science, 2020, 368(6494):eaaz7548.
［13］Yao D D, Bao L L, Li F D, et al. H1N1 influenza virus dose dependent induction of dysregulated innate immune responses and STAT1/3 activation are associated with pulmonary immunopathological damage［J］. Virulence, 2022, 13(1):1558－1572.
［14］Van De Veerdonk F L, Giamarellos-Bourboulis E, Pickkers P, et al. A guide to immunotherapy for COVID-19［J］. Nat Med, 2022, 28(1):39－50.
［15］Sánchez-Borges M, Martin B L, Muraro A M, et al. The importance of allergic disease in public health: an iCAALL statement［J］. World Allergy Organ J, 2018, 11(1):8.
［16］Loftus P A, Wise S K. Epidemiology of asthma［J］. Curr Opin Otolaryngol Head Neck Surg, 2016, 24(3):245－249.
［17］Huang K W, Yang T, Xu J Y, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study［J］. Lancet, 2019, 394(10196):407－418.
［18］Cheng L, Chen J J, Fu Q L, et al. Chinese society of allergy guidelines for diagnosis and treatment of allergic rhinitis［J］. Allergy Asthma Immunol Res, 2018, 10(4):300－353.
［19］Goksr E, Loid P, Alm B, et al. The allergic march comprises the coexistence of related patterns of allergic disease not just the progressive development of one disease［J］. Acta Paediatr, 2016, 105(12):1472－1479.
［20］Murrison L B, Brandt E B, Myers J B, et al. Environmental exposures and mechanisms in allergy and asthma development［J］. J Clin Invest, 2019, 129(4):1504－1515.
［21］Rutkowski K, Sowa P, Rutkowska-Talipska J, et al. Allergic diseases: the price of civilisational progress［J］. Postepy Dermatol Alergol, 2014, 31(2):77－83.
［22］Agache I, Akdis C A. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases［J］. J Clin Invest, 2019, 129(4):1493－1503.
［23］Li Y, Chen S H, Chi Y F, et al. Kinetics of the accumulation of group 2 innate lymphoid cells in IL-33-induced and IL-25-induced murine models of asthma: a potential role for the chemokine CXCL16［J］. Cell Mol Immunol, 2019, 16(1):75－86.
［24］Gasser P, Eggel A. Targeting IgE in allergic disease［J］. Curr Opin Immunol, 2018, 54: 86－92.
［25］Pitlick M M, Pongdee T. Combining biologics targeting eosinophils (IL-5/IL-5R), IgE, and IL-4/IL-13 in allergic and inflammatory diseases［J］. World Allergy Organ J, 2022, 15(11):100707.
［26］Shankar A, McAlees J W, Lewkowich I P. Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease［J］. J Allergy Clin Immunol, 2022, 150(2):266－276.
［27］Parnes J R, Molfino N A, Colice G, et al. Targeting TSLP in asthma［J］. J Asthma Allergy, 2022, 15: 749－765.
［28］Ahmadzadeh M, Johnson L A, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired［J］. Blood, 2009, 114(8):1537－1544.
［29］Goronzy J J, Weyand C M. Mechanisms underlying T cell ageing［J］. Nat Rev Immunol, 2019, 19(9):573－583.
［30］Wherry E J. T cell exhaustion［J］. Nat Immunol, 2011, 12(6):492－499.
［31］Miller B C, Sen D R, Al Abosy R, et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade［J］. Nat Immunol, 2019, 20(3):326－336.
［32］Chihara N, Madi A, Kondo T, et al. Induction and transcriptional regulation of the co-inhibitory gene module in T cells［J］. Nature, 2018, 558(7710):454－459.
［33］Wu T Q, Ji Y, Moseman E A, et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness［J］. Sci Immunol, 2016, 1(6):eaai8593.
［34］Teijeira A, Garasa S, Etxeberria I, et al. Metabolic consequences of T-cell costimulation in anticancer immunity［J］. Cancer Immunol Res, 2019, 7(10):1564－1569.
［35］Zappasodi R, Serganova I, Cohen I J, et al. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours［J］. Nature, 2021, 591(7851):652－658.
［36］Watson M J, Vignali P D A, Mullett S J, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid［J］. Nature, 2021, 591(7851):645－651.
［37］Luoma A M, Suo S B, Williams H L, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy［J］. Cell, 2020, 182(3):655－671.e22.
［38］Bagchi S, Yuan R, Engleman E G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance［J］. Annu Rev Pathol, 2021, 16: 223－249.
［39］Bailey C M, Liu Y, Liu M Y, et al. Targeting HIF-1α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues［J］. J Clin Invest, 2022, 132(9):e150846.
［40］Shi K B, Li H D, Chang T, et al. Bone marrow hematopoiesis drives multiple sclerosis progression［J］. Cell, 2022, 185(13):2234－2247.e17.
［41］Tian D C, Zhang C Y, Yuan M, et al. Incidence of multiple sclerosis in China: a nationwide hospital-based study［J］. Lancet Reg Health West Pac, 2020, 1: 100010.
［42］Cavallo S. Immune-mediated genesis of multiple sclerosis［J］. J Transl Autoimmun, 2020, 3:100039.
［43］Liu J W, Liu L, Kang W T, et al. Cytokines/chemokines: potential biomarkers for non-paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis［J］. Front Neurol, 2020, 11:582296.
［44］Han B, Jiang W, Cui P, et al. Microglial PGC-1α protects against ischemic brain injury by suppressing neuroinflammation［J］. Genome Med, 2021, 13(1):47.
［45］Li J J, Zhao X Q, Meng X, et al. High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome: subanalysis of the clopidogrel in high-risk patients with acute nondisabling cerebrovascular events trial［J］. Stroke, 2016, 47(8):2025－2030.
［46］Meier-Stephenson F S, Meier-Stephenson V C, Carter M D, et al. Alzheimers disease as an autoimmune disorder of innate immunity endogenously modulated by tryptophan metabolites［J］. Alzheimers Dement (N Y), 2022, 8(1):e12283.
［47］Pirooznia S K, Rosenthal L S, Dawson V L, et al. Parkinson disease: translating insights from molecular mechanisms to neuroprotection［J］. Pharmacol Rev, 2021, 73(4):33－97.
［48］Gordon R, Albornoz E A, Christie D C, et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice［J］. Sci Transl Med, 2018, 10(465):eaah4066.
［49］Panicker N, Kam T I, Wang H, et al. Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinsons disease［J］. Neuron, 2022, 110(15):2422－2437.e9.
［50］Walther A, Mackens-Kiani A, Eder J, et al. Depressive disorders are associated with increased peripheral blood cell deformability: a cross-sectional case-control study (Mood-Morph)［J］. Transl Psychiatry, 2022, 12(1):150.
［51］Li Y, Jia Y F, Wang D D, et al. Programmed cell death 4 as an endogenous suppressor of BDNF translation is involved in stress-induced depression［J］. Mol Psychiatry, 2021, 26(6):2316－2333.
［52］Drevets W C, Wittenberg G M, Bullmore E T, et al. Immune targets for therapeutic development in depression: towards precision medicine［J］. Nat Rev Drug Discov, 2022, 21(3):224－244.

[1]	尹雪, 于明航, 王玺, 陈京龙. 肝癌中SWI/SNF复合物突变与免疫检查点抑制剂治疗应答反应的研究进展[J]. 首都医科大学学报, 2023, 44(5): 768-774.
[2]	杨一凡, 王雅梅. 凋亡诱导因子2在乳腺癌中的表达及其相关作用[J]. 首都医科大学学报, 2023, 44(2): 248-257.
[3]	孙婧, 史幼梧, 杜丰, 杨颖, 孙志伟, 余靖, 肖艳洁, 张晓东, 贾军. 消化道肿瘤免疫相关不良事件的临床分析[J]. 首都医科大学学报, 2023, 44(2): 343-350.